





ADULT

OCTREOTIDE

This document should be read in conjunction with this [DISCLAIMER](#)

<p>Presentation</p>	<p>Injection: 100microg/mL Injection: 500microg/mL</p>
<p>Dose</p>	<p><i>Rarely used and no longer recommended by Therapeutic Guidelines®; seek advice from palliative care consultant.</i></p> <p><u>Bowel obstruction</u></p> <p>Subcut injection, IV: 50 - 100microg 2 to 3 times a day</p> <p>Subcut infusion: 300microg/24 hours. Can be titrated up to 900microg per 24hours if required but usually in the range of 300 - 600microg per 24hours</p>
<p>Administration</p>	<p><u>Subcut</u></p> <p>Reconstitution: Allow to reach room temperature for at least 30 minutes before use.</p> <p>Administration: Can be given intermittent injection or as a continuous subcutaneous infusion. Rotate the site of the injection.</p> <p><u>Intravenous infusion (intermittent)</u></p> <p>Reconstitution: Allow to reach room temperature for at least 30 minutes before use.</p> <p>Dilution: Dilute dose in 50-200mL of Sodium Chloride 0.9%.</p> <p>Administration: Infuse over 15 to 30 minutes</p> <p><u>Intravenous infusion (continuous)</u></p> <p>Reconstitution: Allow to reach room temperature for at least 30 minutes before use.</p> <p>Dilution: Dilute 500 microgram in 500 mL of Sodium Chloride 0.9%. Concentration is 1microg/mL.</p> <p>Administration: Infuse continuously at 25–50 microgram/hou (25–50 mL/hour)</p>

	<p><u>Intravenous injection (emergency situations)</u></p> <p>Reconstitution: Allow to reach room temperature for at least 30 minutes before use.</p> <p>Dilution: Dilute 1mL with 2-10mL of Sodium Chloride 0.9%.</p> <p>Administration: Inject over 3-5 minutes</p>
Pregnancy	<p>1st Trimester: Consider alternative</p> <p>2nd Trimester: Consider alternative</p> <p>3rd Trimester: Consider alternative</p>
Breastfeeding	Consider alternative
Clinical Guidelines and Policies	<p>Palliative Care</p> <p>Niki T34 Syringe Pump: Management of Continuous Subcutaneous Infusion</p> <p>FSH Pharmacy Department: Intravenous Drug Administration Guideline: Octreotide</p>
References	<p>Society of Hospital Pharmacists of Australia. Octreotide. In: Australian Injectable Drugs Handbook [Internet]. [St Leonards, New South Wales]: Health Communication Network; 2017 [cited 2017 April 13]. Available from: http://aidh.hcn.com.au</p> <p>The Royal Women's Hospital. Folic acid. In: Pregnancy and Breastfeeding Medicines Guide [Internet]. Parkville (Victoria): The Royal Women's Hospital; 2016 [cited 2017 Apr 12]. Available from: https://thewomenspbmg.org.au/</p> <p>Australian Medicines Handbook. Octreotide. In: Australian Medicines Handbook [Internet]. Adelaide (South Australia): Australian Medicines Handbook; 2017 [cited 2017 Apr 12]. Available from: https://amhonline.amh.net.au/</p> <p>Therapeutic Guidelines. Bowel obstruction in palliative care. In: eTG complete [Internet]. West Melbourne (Victoria): Therapeutic Guidelines; 2017 [cited 2017 Apr 12]. Available from: https://tgldcdp.tg.org.au</p> <p>MIMS Australia. Octreotide MaxRx. In: MIMS Online [Internet]. St Leonards (New South Wales): MIMS Australia; 2016 [cited 2017 Apr 12]. Available from: https://www.mimsonline.com.au</p>

Keywords:	Octreotide, bowel obstruction, palliative care		
Publishing:	<input checked="" type="checkbox"/> Intranet <input checked="" type="checkbox"/> Internet		
Document owner:	Chief Pharmacist		
Author / Reviewer:	KEMH Pharmacy Department		
Date first issued:	April 2015	Version:	3.0
Last reviewed:	November 2017	Next review date:	11/2020
Endorsed by:	Medicines and Therapeutics Committee	Date:	
Standards Applicable:	NSQHS Standards: 1  Clinical Care is Guided by Current Best Practice 4  Medication Safety		
Printed or personally saved electronic copies of this document are considered uncontrolled. Access the current version from the WNHS website.			